Compare RAMP & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RAMP | VCEL |
|---|---|---|
| Founded | 2018 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1994 | 1996 |
| Metric | RAMP | VCEL |
|---|---|---|
| Price | $25.72 | $29.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $35.60 | ★ $58.50 |
| AVG Volume (30 Days) | ★ 717.9K | 610.3K |
| Earning Date | 02-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | ★ 1.14 | 0.32 |
| Revenue | ★ $745,580,000.00 | $276,259,000.00 |
| Revenue This Year | $11.20 | $19.10 |
| Revenue Next Year | $9.18 | $17.95 |
| P/E Ratio | ★ $22.72 | $96.31 |
| Revenue Growth | 13.02 | ★ 16.45 |
| 52 Week Low | $21.71 | $29.24 |
| 52 Week High | $35.20 | $45.97 |
| Indicator | RAMP | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 41.13 | 30.35 |
| Support Level | $24.83 | N/A |
| Resistance Level | $29.05 | $38.48 |
| Average True Range (ATR) | 1.01 | 1.52 |
| MACD | -0.39 | -0.18 |
| Stochastic Oscillator | 11.11 | 9.09 |
LiveRamp Holdings Inc is a technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics, and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust. The Company provides a data collaboration platform, essentially acting as a data collaboration hub where businesses can securely share and manage first-party consumer data with trusted partners while prioritizing data privacy and ethics.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.